Browsing Centre for Haemato-Oncology by Title

THE ADDITION OF RITUXIMAB TO CODOX-M/IVAC CHEMOTHERAPY IN THE TREATMENT OF BURKITT LYMPHOMA IS SAFE AND IS ASSOCIATED WITH INCREASED EFFICACY IN THE HIV POSITIVE POPULATION

Alwan, F; He, A; Montoto, S; Kassam, S; Mee, M; Burns, F; Edwards, S; Wilson, A; Tenant-Flowers, M; Marcus, R (2014-06-01)

The Ageing Brain: Effects on DNA Repair and DNA Methylation in Mice

Langie, SAS; Cameron, KM; Ficz, G; Oxley, D; Tomaszewski, B; Gorniak, JP; Maas, LM; Godschalk, RWL; van Schooten, FJ; Reik, W (2017-02)

Alternative donors extend transplantation for patients with lymphoma who lack an HLA matched donor

Bachanova, V; Burns, LJ; Wang, T; Carreras, J; Gale, RP; Wiernik, PH; Ballen, KK; Wirk, B; Munker, R; Rizzieri, DA (2015-02)

Augmenting Autologous Stem Cell Transplantation to Improve Outcomes in Myeloma

Maybury, B; Cook, G; Pratt, G; Yong, K; Ramasamy, K (Elsevier BV, 2016-11)

Autologous stem cell transplantation in refractory Crohn's disease - low intensity therapy evaluation (ASTIClite): study protocols for a multicentre, randomised controlled trial and observational follow up study

Snowden, JA; Hawkey, C; Hind, D; Swaby, L; Mellor, K; Emsley, R; Mandefield, L; Lee, E; Badoglio, M; Polge, E (2019-05-31)

Autophagy mediates degradation of nuclear lamina

Dou, Z; Xu, C; Donahue, G; Shimi, T; Pan, J-A; Zhu, J; Ivanov, A; Capelll, BC; Drake, AM; Shah, PP (2015-11-05)

BIM mediates synergistic killing of B-cell acute lymphoblastic leukemia cells by BCL-2 and MEK inhibitors

Korfi, K; Smith, M; Swan, J; Somervaille, TCP; Dhomen, N; Marais, R (2016-04)

Blocking Autophagy Prevents Bortezomib-Induced NF-kappa B Activation by Reducing I-kappa B alpha Degradation in Lymphoma Cells

Jia, L; Gopinathan, G; Sukumar, JT; Gribben, JG (2012-02-29)

CD160 signaling mediates PI3K-dependent survival and growth signals in chronic lymphocytic leukemia

Liu, FT; Giustiniani, J; Farren, T; Jia, L; Bensussan, A; Gribben, JG; Agrawal, SG (2010-04-15)

Chloroquine targets pancreatic cancer stem cells via inhibition of CXCR4 and hedgehog signaling.

Balic, A; Sørensen, MD; Trabulo, SM; Sainz, B; Cioffi, M; Vieira, CR; Miranda-Lorenzo, I; Hidalgo, M; Kleeff, J; Erkan, M (2014-07)

Pancreatic ductal adenocarcinoma is one of the deadliest carcinomas and is characterized by highly tumorigenic and metastatic cancer stem cells (CSC). CSCs evade available therapies, which preferentially target highly ...

CLOFARABINE IN COMBINATION WITH HIGH-DOSE CYTARABINE AND LIPOSOMAL DAUNORUBICIN IN PEDIATRIC AML: RESULTS OF A PHASE 1 COMBINATION STUDY BY THE ITCC CONSORTIUM

Zwaan, CM; Dworzak, M; Klingebiel, T; Roessig, C; Leverger, G; Stary, J; de Bont, ES; Niemeyer, CM; Kaspers, GJ; Bertrand, Y (2014-12)

The combination of CHK1 inhibitor with G-CSF overrides cytarabine resistance in human acute myeloid leukemia.

Di Tullio, A; Rouault-Pierre, K; Abarrategi, A; Mian, S; Grey, W; Gribben, J; Stewart, A; Blackwood, E; Bonnet, D (2017-11-22)

Cytarabine (AraC) represents the most effective single agent treatment for AML. Nevertheless, overriding AraC resistance in AML remains an unmet medical need. Here we show that the CHK1 inhibitor (CHK1i) GDC-0575 enhances ...

Contrasting requirements during disease evolution identify EZH2 as a therapeutic target in AML

Basheer, F; Giotopoulos, G; Meduri, E; Yun, H; Mazan, M; Sasca, D; Gallipoli, P; Marando, L; Gozdecka, M; Asby, R (Rockefeller University Press, 2019-03-19)

Epigenetic regulators, such as EZH2, are frequently mutated in cancer, and loss-of-function EZH2 mutations are common in myeloid malignancies. We have examined the importance of cellular context for Ezh2 loss during the ...

A CRISPR Dropout Screen Identifies Genetic Vulnerabilities and Therapeutic Targets in Acute Myeloid Leukemia

Tzelepis, K; Koike-Yusa, H; De Braekeleer, E; Li, Y; Metzakopian, E; Dovey, OM; Mupo, A; Grinkevich, V; Li, M; Mazan, M (2016-10-18)

Current challenges in software solutions for mass spectrometry-based quantitative proteomics

Cappadona, S; Baker, PR; Cutillas, PR; Heck, AJR; van Breukelen, B (2012-09)

Dangerous power: mitochondria in CLL cells.

JIA, L; Gribben, GJ (American Society of Hematology, 2014-04-24)

Development and validation of an ultra-high performance LC-MS/MS assay for intracellular SN-38 in human solid tumour cell lines: Comparison with a validated HPLC-fluorescence method

Ghazaly, E; Perry, J; Kitromilidou, C; Powles, T; Joel, S (2014-10-15)

Development of HPLC-UV method for rapid and sensitive analysis of topically applied tetracaine: its comparison with a CZE method

Al-Otaibi, F; Ghazaly, E; Johnston, A; Perrett, D (2014-06)

Diabetes-Related Autoantibodies in Children With Acute Lymphoblastic Leukemia

Bizzarri, C; Pinto, RM; Pitocco, D; Astorri, E; Cappa, M; Hawa, M; Giannone, G; Palermo, A; Maddaloni, E; Leslie, DRG (2012-03)

A distinct plasmablast and naive B-cell phenotype in primary immune thrombocytopenia

Flint, SM; Gibson, A; Lucas, G; Nandigam, R; Taylor, L; Provan, D; Newland, AC; Savage, CO; Henderson, RB (2016-06)